Key insights include:
- Precision oncology advances driving radiopharmaceutical innovation and adoption.
- Rising global trial activity and early-phase development.
- Strong market momentum with growing interest in targeted alpha therapies.
- CRO capabilities essential for navigating complex approvals, logistics, and global trial execution.
DOWNLOAD OUR LATEST WHITE PAPER TO EXPLORE THE GLOBAL CLINICAL TRIAL LANDSCAPE, MARKET TRENDS, AND CRO STRATEGIES SHAPING THE FUTURE OF THERAPEUTIC RADIOPHARMACEUTICALS.
Therapeutic radiopharmaceuticals are redefining precision oncology by delivering targeted radiation using radioisotopes linked to tumor-specific molecules. This targeted approach reduces off-target effects and improves treatment outcomes in cancers like neuroendocrine tumors, prostate, thyroid, and hematologic malignancies.
Global trials have risen sharply, from just a few in 2018 to over 80 by mid-2025, driven by advances in alpha and beta emitters, strong clinical outcomes, and FDA designations. With most trials in early phases, late-phase activity is rising in resistant tumors. However, supply-chain complexity and short half-lives present challenges to broader adoption.
A growing pipeline of agents—such as Lutetium-177, Actinium-225, and Lead-212—is transforming treatment possibilities. Alpha therapies, in particular, offer high-precision tumor cell kill and show strong potential in sanctuary sites and micro-metastases. Innovation in delivery platforms, combination regimens, and manufacturing scale-up is central to mitigating supply challenges and meeting global demand. As radiopharmaceuticals continue evolving, expanding into new cancer indications, global sponsor interest is rising—driving strategic partnerships with CROs to accelerate development and streamline trial execution.
Authored by Novotech, a leading global biotech CRO, this whitepaper delivers a comprehensive look at the research landscape, market growth, regulatory dynamics, and emerging science in radiopharmaceutical development.